Skip to main content
OpenTrials
Completed

NCT Number: NCT03120013

Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia

Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ataxia, Cerebellar Ataxia Ataxia With Oculomotor Apraxia Ataxia, Spinocerebellar Autonomic Nervous System Diseases Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Cerebellar Ataxia Cerebellar Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dyskinesias Friedreich Ataxia Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Machado-Joseph Disease Metabolic Diseases Mitochondrial Diseases Movement Disorders Multiple System Atrophy Nervous System Diseases Neurodegenerative Diseases Neurologic Manifestations Nutritional and Metabolic Diseases Pathological Conditions, Signs and Symptoms Primary Dysautonomias Signs and Symptoms Spinal Cord Diseases Spinocerebellar Ataxia 3 Spinocerebellar Ataxia Type 1 Spinocerebellar Ataxia Type 2 Spinocerebellar Ataxias Spinocerebellar Degenerations Spinocerebellar ataxia, autosomal recessive 1 Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

AO Spedali Civili

Brescia, BS, 25100, Italy

About this study

Neurodegenerative cerebellar ataxias represent a heterogeneous group of disabling disorders in which progressive ataxia of gait, limb dysmetria, oculomotor deficits, dysarthria and kinetic tremor are the prominent clinical manifestations. Both the hereditary and sporadic forms usually present in young adulthood, and are characterized by atrophy of cerebellar or brainstem structures. Currently, cerebellar ataxia lack effective disease-modifying therapies.

Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. The present randomized, double-blind, sham-controlled study will investigate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

Subjects will be randomized in two groups, one receiving a 10 day (5 days/week for 2 weeks) treatment with anodal cerebellar and cathodal spinal tDCS and the other receiving sham stimulation with identical parameters. After the intervention, patients will be reassessed with a clinical and neurophysiological evaluation at 2 weeks, 1 months and 3 month after treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with a cerebellar syndrome and quantifiable cerebellar atrophy

Exclusion criteria

  • Severe head trauma in the past
  • History of seizures
  • History of ischemic stroke or hemorrhage
  • Pacemaker
  • Metal implants in the head/neck region
  • Severe comorbidity
  • Intake of illegal drugs
  • Pregnancy

Treatment and study plan

Anodal cerebellar and cathodal spinal tDCS

Device

10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)

Sham cerebellar and sham spinal tDCS

Device

10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)

Primary outcomes

  1. Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline

    Time frame: Baseline - 2 weeks

    International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia).

  2. Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline

    Time frame: Baseline - 2 weeks

    Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).

Secondary outcomes

  1. Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline

    Time frame: Baseline - 2 weeks - 1 month - 3 months

    International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia).

  2. Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline

    Time frame: Baseline - 2 weeks - 1 month - 3 months

    Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia).

  3. Change in the 9 Hole Peg Test (9HPT) Score From Baseline

    Time frame: Baseline - 2 weeks - 1 month - 3 months

    4 timed trials of the 9 hole peg test (9HPT) were performed and averaged (mean values are reported) for each separate hand (dominant and nondominant). The total time to complete the task is recorded for each trial and for each separate hand (dominant and nondominant). Longer times represent greater impairment.

  4. Change in the 8-Meter Walking Time (8MW) Score From Baseline

    Time frame: Baseline - 2 weeks - 1 month - 3 months

    4 timed trials of the 8 meter walking time (8MW) were performed and averaged (mean values are reported). Longer times represent greater impairment.

  5. Change in Cerebellar Brain Inhibition (CBI) Measurements From Baseline

    Time frame: Baseline - 2 weeks - 1 month - 3 months

    Cerebellar brain inhibition (CBI) is expressed as motor evoked potential amplitude (average of 10 recordings). Lower values reflect higher inhibition and thus reduced impairment.

  6. Change in the Short-Form Health Survey 36 (SF36) Score From Baseline

    Time frame: Baseline - 2 weeks - 1 month - 3 months

    The Italian version of the Short-Form Health Survey 36 (SF-36): consists of 36 scaled score, yielding a total score of 0 (more disability) to 100 (less disability).

Sponsors and collaborators

Lead sponsor

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Other

Registry information

Official study title

Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia

Acronym: CStDCSAtaxia

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Apr 19, 2017
Registry last updated
Mar 3, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.